Business Model:
Revenue: $0
Employees: 0-0
Address:
City:
State:
Zip:
Country:
Prospect Venture Partners is a venture capital firm with over $1B of capital under management. The firm is dedicated to investing in outstanding biopharmaceutical and medical device companies. Prospect targets commercially attractive biomedical enterprises with outstanding entrepreneurial management teams, proprietary products, and innovative technologies with the potential for significant investment returns. The firm invests in companies with a wide variety of development and financing requirements including new company incubations, first and second venture financing rounds, and later stage private and public companies with proven business models requiring expansion capital.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
6/2002 | Infinity Pharmaceuticals | Series B | 0 |
9/2006 | Alvine Pharmaceuticals | Series A | 21.5M |
12/2003 | Portola Pharmaceuticals | Series A | 21M |
11/2005 | Portola Pharmaceuticals | Series B | 46M |
7/2008 | Portola Pharmaceuticals | Series C | 60.1M |
8/2003 | Rinat Neuroscience | Series B | 40M |
4/2003 | Nanosys | Series B | 0 |
7/2003 | Tercica | Series B | 44M |
6/2004 | Idun Pharmaceuticals | Venture Round | 0 |
5/2004 | Amicus Therapeutics | Series B | 31M |
9/2006 | Amicus Therapeutics | Series D | 60M |
8/2005 | Amira Pharmaceuticals | Series A | 3M |
5/2002 | AVEO Oncology | Series A | 15M |
1/2011 | Satori Pharmaceuticals | Series B | 7M |
10/2003 | AVEO Oncology | Series B | 42.7M |
3/2015 | NGM Biopharmaceuticals | Series D | 57.5M |
4/2008 | Transave | Series D | 35M |
7/2013 | NGM Biopharmaceuticals | Series C | 50M |
9/2016 | SentreHEART | Series D | 35M |
5/2006 | Cogentus Pharmaceuticals | Series A | - |
5/2009 | Visiogen | Series D | 40M |
9/2006 | Alvine Pharmaceuticals | Series A | 8M |
10/2004 | Vanda Pharmaceuticals | Series B | 18.5M |
12/2007 | Cogentus Pharmaceuticals | Series C | 62.5M |
11/2005 | Hansen Medical | Venture Round | - |
4/2005 | Allux Medical | Series B | 5M |
2/2002 | Metreo | Series C | 15M |
4/2008 | DFine | Series D | 20M |
12/2005 | DFine | Series B | 6.5M |
12/2009 | NGM Biopharmaceuticals | Series A | 26.6M |
7/2006 | Pathwork Diagnostics | Venture Round | 11M |
7/2005 | Vitae Pharmaceuticals | Series C | 15M |
3/2007 | Amira Pharmaceuticals | Series B | 25M |
4/2007 | Cogentus Pharmaceuticals | Series B | 15M |
10/2004 | Gloucester Pharmaceuticals | Series B | 29M |
11/2007 | Vitae Pharmaceuticals | Series D | 15M |
3/2014 | Element Science | Series A | 12.5M |
6/2005 | Verus Pharmaceuticals | Series A | 0 |
2/2012 | Satori Pharmaceuticals | Venture Round | 15M |
10/2011 | Azelon Pharmaceuticals | Series A | 4.5M |
11/2006 | Amira Pharmaceuticals | Series A | 4M |
9/2011 | Kythera Biopharmaceuticals | Series D | 0 |
3/2004 | Jazz Pharmaceuticals | Series B | 0 |
1/2004 | Vitae Pharmaceuticals | Series B | 15M |
6/2005 | Somaxon Pharmaceuticals | Series C | 0 |
9/2004 | Allux Medical | Series A | 800k |
5/2005 | AVEO Oncology | Series C | 5M |
2/2007 | Visiogen | Venture Round | 24M |
3/2014 | NinePoint Medical | Series B | 34M |
10/2011 | Topica Pharmaceuticals | Series B | 27M |
1/2010 | DFine | Venture Round | 0 |
8/2002 | Biospect | Series A | 4M |
6/2007 | Roxro Pharma | Series B | 42.7M |
6/2003 | Opus Medical | Series C | 13.6M |
1/2009 | DFine | Venture Round | 0 |
10/2005 | Roxro Pharma | Series B | 21.6M |
3/2002 | Signature BioScience | Series E | 0 |
8/2002 | Archemix | Series A | 51.8M |
11/2011 | DFine | Venture Round | 25M |
7/2010 | DFine | Venture Round | 36.2M |
1/2011 | SurePoint Medical | Venture Round | - |
8/2009 | Gloucester Pharmaceuticals | Series D | 29M |
3/2008 | SurgRx | Series G | 19.8M |
7/2004 | Trubion Pharmaceuticals | Series B | 32M |
6/2004 | Rejuvenon | Series B | 37M |
8/2010 | Complete Genomics | Series E | 39M |
11/2005 | Nanosys | Series C | 0 |
4/2007 | Aspen MedTech | Venture Round | 1M |
11/2011 | NGM Biopharmaceuticals | Series B | 55.4M |
6/2012 | SentreHEART | Series C | 26M |
9/2004 | SurgRx | Series D | 11.9M |
4/2007 | SurgRx | Series F | 20M |
4/2014 | Nora Therapeutics | Series B | 18M |
9/2008 | Baxano | Series B | 20M |
7/2007 | Neomend | Series C | 6M |
1/2009 | Satori Pharmaceuticals | Series A | 22M |
1/2010 | Neomend | Series D | 30M |
10/2010 | NinePoint Medical | Series A | 33M |
3/2004 | Phylogix Inc. | Series B | 12M |
5/2008 | Kythera Biopharmaceuticals | Series C | 0 |
4/2004 | Archemix | Series B | 50M |
10/2010 | Pathwork Diagnostics | Series C | 30M |
6/2010 | Baxano | Series C | 30M |
2/2002 | Nanosys | Series A | 15M |
7/2006 | Kythera Biopharmaceuticals | Series B | 30M |
8/2009 | Complete Genomics | Series D | 45M |
10/2009 | Lux Biosciences | Series B | 50M |
9/2005 | Amicus Therapeutics | Series C | 55M |
7/2009 | Somaxon Pharmaceuticals | Post-IPO Equity | 6M |
9/2016 | SentreHEART | Series D | 0 |
3/2015 | NGM Biopharmaceuticals | Series D | 0 |
4/2014 | Nora Therapeutics | Series B | 0 |
3/2014 | Element Science | Series A | 0 |
3/2014 | NinePoint Medical | Series B | 0 |
7/2013 | NGM Biopharmaceuticals | Series C | 0 |
6/2012 | SentreHEART | Series C | 0 |
2/2012 | Satori Pharmaceuticals | Venture Round | 0 |
11/2011 | DFine | Venture Round | 0 |
11/2011 | NGM Biopharmaceuticals | Series B | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|